Alector reports inducement grants under nasdaq listing rule 5635(c)(4)

South san francisco, calif., oct. 06, 2022 (globe newswire) -- alector, inc. (nasdaq: alec), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that on october 1, 2022, the compensation committee of alector's board of directors granted six new employees options to purchase an aggregate of 103,462 shares of the company's common stock and restricted stock units (rsus) for an aggregate of 51,730 shares of the company's common stock. these awards are made under alector's 2022 inducement equity incentive plan (the “plan”).
ALEC Ratings Summary
ALEC Quant Ranking